NCI CTEP-Approved Trials for the Month of May

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.


Phase II

9543: A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients with Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL). MD Anderson Cancer Center; Burger, Jan A. (713) 792-1865

AMC-089: A Phase II Study of Gamma Secretase Inhibitor PF-03084014 in Patients with AIDS-Associated Kaposi Sarcoma. AIDS-Associated Malignancies Clinical Trials Consortium; Ratner, Lee. (314) 362-8836

CITN-07-FLT3L: A Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand. Cancer Immunotherapy Trials Network; Bhardwaj, Nina. (212) 263-5814


Phase Other

AALL14B1-Q: Deep Sequencing for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia ALL. Children’s Oncology Group; Wood, Brent Lee. (206) 288-7115

AAML14B4-Q: Role of EVI-1 Hyperexpression in Pediatric and Young Adult Acute Myeloid Leukemia. Children’s Oncology Group; Qian, Zhijian. (312) 355-3295

EA914LT1: Lab Testing of AML Patient Samples. ECOG-ACRIN Cancer Research Group; Wald, David. (216) 368-5668

S0016B: Use of Chromosome Genomic Microarray Testing (CGAT) to Identify Novel Genetic Aberrations Impacting Patient Outcome in S0016 Follicular Lymphoma Patients. SWOG; Fang, Min (206) 288-1385


Pilot Phase

ABTC-1301: Pilot Study of MLN0128 in Preoperative Recurrent Glioblastoma (GBM) Patients. Adult Brain Tumor Consortium; Lee, Eudocia Quant. (617) 632-2166

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login